Clinical and Pathological Evidence of Anti-GD2 Immunotherapy Induced Differentiation in Relapsed/Refractory High-Risk Neuroblastoma

SIMPLE SUMMARY: The anti-tumor activity of anti-GD2 monoclonal antibodies (mAbs) have been demonstrated by the capacity to mediate immunological cytotoxicity but also through direct cell death induction. Recently, studies with anti-GD2 mAbs for high-risk (HR)-neuroblastoma (NB) patients with measura...

Descripción completa

Detalles Bibliográficos
Autores principales: Mora, Jaume, Castañeda, Alicia, Colombo, Maria Cecilia, Gorostegui, Maite, Gomez, Fernando, Mañe, Salvador, Santa-Maria, Vicente, Garraus, Moira, Macias, Napoleon, Perez-Jaume, Sara, Muñoz, Oscar, Muñoz, Juan Pablo, Barber, Ignasi, Suñol, Mariona
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7998131/
https://www.ncbi.nlm.nih.gov/pubmed/33809255
http://dx.doi.org/10.3390/cancers13061264

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7998131/
https://www.ncbi.nlm.nih.gov/pubmed/33809255
http://dx.doi.org/10.3390/cancers13061264

Ejemplares similares